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Abstract
Background: It is possible to infer the past of populations by comparing genomes between individuals. In general, older
populations have more genomic diversity than younger populations. The force of selection can also be inferred from
population diversity. If selection is strong and frequently eliminates less fit variants, diversity will be limited because new,
initially homogeneous populations constantly emerge.
Methodology and Results: Here we translate a population genetics approach to human somatic cancer cell populations by
measuring genomic diversity within and between small colorectal cancer (CRC) glands. Control tissue culture and xenograft
experiments demonstrate that the population diversity of certain passenger DNA methylation patterns is reduced after
cloning but subsequently increases with time. When measured in CRC gland populations, passenger methylation diversity
from different parts of nine CRCs was relatively high and uniform, consistent with older, stable lineages rather than mixtures
of younger homogeneous populations arising from frequent cycles of selection. The diversity of six metastases was also
high, suggesting dissemination early after transformation. Diversity was lower in DNA mismatch repair deficient CRC glands,
possibly suggesting more selection and the elimination of less fit variants when mutation rates are elevated.
Conclusion/Significance: The many hitchhiking passenger variants observed in primary and metastatic CRC cell populations
are consistent with relatively old populations, suggesting that clonal evolution leading to selective sweeps may be rare after
transformation. Selection in human cancers appears to be a weaker than presumed force after transformation, consistent
with the observed rarity of driver mutations in cancer genomes. Phenotypic plasticity rather than the stepwise acquisition of
new driver mutations may better account for the many different phenotypes within human tumors.
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Introduction
A barrier to a better understanding of human cancer is the
inability to directly observe how cancers evolve. Progression is
clinically important, with localized cancers more easily treated
than deeply invasive or metastatic cancers. A logical presumption
is that progression occurs stepwise after transformation (Fig 1) with
the sequential selection of new driver mutations and more
malignant phenotypes by clonal evolution [1] as tumor cells
encounter and then colonize new microenvironments. However, a
recent cancer genome sequencing study [2] illustrated that
metastases have relatively few additional mutations compared to
their primary colorectal cancers (CRCs). Approximately 97% of
the mutations present in the metastases were also detected in their
primary tumors, and the few additional mutations did not have
obvious metastatic roles.
Alternatively, the ability to invade or metastasize may already be
present at the time of transformation [3], allowing for progression
without further clonal evolution (Fig 1). Phenotypic differences
between tumor cells would arise secondary to phenotypic plasticity
[4,5] rather than the acquisition of new driver mutations. A key
difference between these models is the efficiency of selection to act
upon variant cells that inevitably accumulate with time. Selection
depends on variation, but selection may not easily discriminate
between cancer cells because most mutations appear to be neutral
passenger mutations [6,7]. Although positive or negative selection is
difficult to quantify, there is a long history of using the variation at
neutralor hitchhiking passengerlociwithina population to measure
the force of selection, which opposes drift by eliminating less fit
variants [8]. Because neutral passenger changes are more common
than driver changes [6,7],manypassengerchanges mayaccumulate
within tumor populations between selective sweeps.
Tumor heterogeneity measurements are complicated because
many mechanisms can contribute to diversity [4]. Measuring the
diversity in a large tumor population is problematic because if
selection is strong, many different variants may be selected, each
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of a tumor. To minimize environmental heterogeneity and
because the most immediate battle for survival occurs between
adjacent cells, a sensitive test for selection is the amount of
variation among small groups of neighboring cells within a single
microenvironment, especially since fixation is faster in smaller
populations [9]. Although progeny of a single selected cell may
not sweep widely, at a minimum selection should be able to
homogenize its immediate neighborhood and microenvironment.
Extensive heterogeneity between adjacent cancer cells would
suggest selection does not frequently optimize fitness even within
small populations.
Colorectal adenocarcinomas have neoplastic glands that
partition tumor cells into distinct small neighborhoods. The extent
of hitchhiking diversity within and between glands depends on the
timing of the last clonal expansion or selective sweep (Fig 2). A
selected variant cell and its progeny would initially dominate its
gland and could subsequently form additional neighboring glands,
creating a focal population with relatively uniform diversity. At
its extreme, an entire tumor may be created by a single clonal
expansion. Here we measure cancer genome passenger DNA
methylation pattern variation within small (2,000 to 10,000 cell)
gland fragments from different parts of the same human CRCs
and infer clonal evolutionary bottlenecks occur infrequently after
transformation.
Results
Detecting Selection and Clonal Evolution in an
Experimental System
Because somatic mutations are relatively rare in human CRCs
(,1 per 100,000 bases [6,10]), we have employed the 59 to 39
order of passenger DNA methylation at short CpG rich regions as
epigenetic somatic cell molecular clocks [11]. The 59 to 39 order of
Figure 1. Two progression models. Stepwise selection and clonal
evolution creates populations of different diversities and phenotypes
because they are created at different times from different progenitors
after transformation. By contrast, the diversity of a single clonal expansion
is relatively uniform.
doi:10.1371/journal.pone.0021657.g001
Figure 2. Hitchhiking neutral or passenger methylation. A male cancer cell contains a single methylation pattern on a CpG rich region of the
X-chromosome. The passenger methylation pattern will drift and hitchhike with the fate of its cell. After clonal expansion, the cancer cell population
will be initially homogeneous but variant cells (different colors) and passenger methylation patterns will arise from drift (replication errors). A diverse
population has three fates. If no selection occurs, a population will continue to drift and become more diverse. Strong positive selection of a variant
(blue) cell results in a sweep or clonal evolution, with homogenization of the population and hitchhiking passenger methylation. Weak negative or
background selection leads to loss of a variant cell (blue) and a reduction in the diversity of the hitchhiking methylation patterns. Therefore, the
strength of selection can be inferred by measuring the PWDs of hitchhiking passenger methylation patterns within a population.
doi:10.1371/journal.pone.0021657.g002
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measure genomic variation, which should hitchhike with the fates
of their cells (Fig 2). Passenger methylation patterns should be
initially homogeneous and subsequently become increasingly
polymorphic after a clonal evolution bottleneck. In the first
experiments, we verify that these passenger methylation patterns
or tags can record a simple clonal evolution cycle: polyclonal
population R monoclonal population R polyclonal population.
This bottleneck (Fig 2) can be simulated by cloning and then
expanding single cells in tissue culture and subsequently as
subcutaneous xenografts in nude mice (Fig 3A). X-chromosome
tags (BGN and LOC, tag sequences and sample data are provided
in Fig S1) and a male diploid CRC cell line (Lovo) were examined
(a single epiallele per cell). The LOC tag appears to have a higher
replication error rate than the BGN tag [12], and therefore should
become polymorphic faster. Epialleles were sampled by bisulfite
sequencing cloned PCR products of DNA extracted from the cul-
tures or small xenograft fragments (5 to 6 fragments per xenograft,
Figure 3. Experimental clonal evolution. A. Schematic of the Lovo single cell cloning, first in culture and then as xenografts, simulating a clonal
evolution bottleneck. B. Hitchhiking diversity decreases and then increases in culture and the xenografts after single cell cloning. (X’s represent
independent single cell clones in culture, and O’s represent PWD averages among tags isolated from 5 to 6 small xenograft fragments) The LOC tag
has a higher error rate compared to the BGN tag [12], and more quickly restores the diversity seen in polyclonal populations. C. Comparisons
between fragments demonstrate intergland PWDs are smaller between clonally related tumors and larger between unrelated tumors, indicating the
ability of the LOC or BGN tags to identify and distinguish between new and older clonal expansions (circles are averages of the fragment comparisons
between the different xenografts, and bars are overall averages) D. Xenograft intragland PWDs are typically nearly as large as their intergland PWDs,
indicating that the small tumor fragments are almost as diverse as their tumors.
doi:10.1371/journal.pone.0021657.g003
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pairwise distance (PWD).
The polyclonal culture and small fragments of its xenografts
were diverse populations, with many different tag patterns and
relatively high PWDs (Fig 3). After single cell cloning, tag diversity
decreased but subsequently increased. This reduction and
subsequent increase in tag diversity after single cell cloning was
not strictly clock-like because some younger clones were more
diverse than some older clones (Fig 3B). However, tag pattern
changes generally recorded the experimental clonal evolution
scenario of a single cell bottleneck followed by clonal expansion
and an increase in PWDs.
Detecting Stepwise Progression In An Experimental
System
The above studies measured diversity within single tumor gland
fragments. Another method to measure diversity is to compare
epialleles from different parts of the same tumor. Here PWDs
between cells are compared with physical distances between cells
to ask whether adjacent cells are more related than distant cells.
With a single rapid clonal expansion (a star phylogeny), distant
cells are almost related as adjacent cells because its different parts
are essentially created at the same time. Therefore, PWDs will be
independent of physical distance or location. By contrast, if tumors
are created by stepwise selection and clonal evolution, PWDs
depend on the physical location of the cells. Older regions should
be more diverse than younger regions, and PWDs should increase
when comparisons are made between younger and older tumor
regions (Fig 1).
The xenografts simulate these different progression scenarios. A
single recent clonal expansion is represented by xenografts
initiated from the same single cell progenitor. Stepwise clonal
evolution is represented by comparisons between the polyclonal
and clonal xenografts. Intergland PWDs were lower in the clonal
xenografts, greater in the polyclonal xenografts, and greater
between the clonal xenografts and their parental polyclonal
xenografts or the other independent clonal xenograft (Fig 3C).
These experiments demonstrate that passenger methylation tags
can distinguish a single clonal expansion from tumors composed of
different aged populations.
Lack of Bottlenecks During Xenograft Formation
The cloning experiments are potentially complicated by unseen
bottlenecks caused by natural selection (Fig 2). The ‘‘polyclonal’’
nature of the Lovo cell line in tissue culture before single cell
cloning may not be unexpected because this is a long established
cell line [13], and presumably progeny are similarly fit. However,
bottlenecks may occur during xenograft formation because only
some cells within a tissue culture adapted cell line may thrive in a
nude mouse microenvironment. Indeed, xenograft growth may
not be visible when less than a million cells are inoculated, a
phenomenon often employed to measure frequencies of ‘‘cancer
initiating cells’’, which may represent cancer stem cells (CSCs)
[14]. Bottlenecks may also occur if different microenvironments
encountered during growth efficiently select only the fittest
variants, to yield localized clonal evolution.
If significant bottlenecks occur during tumorigenesis, xenograft
diversities will be similarly limited whether the initial inoculate was
clonal or polyclonal. BGN tag diversity was significant less when
xenografts were initiated with the single cell clones compared with
a polyclonal inoculate (average intragland PWDs of 1.2 versus 2.1,
p=0.007), indicating that selective bottlenecks do not occur with
the Lovo cell line during xenograft tumorigenesis (Fig 3B). LOC
tag diversity was similar between clonal and polyclonal xenograft
fragments (average intragland PWDs of 2.5 versus 2.4, p=0.86),
but the LOC tag appears to have a higher replication error rate
than BGN [12]. Therefore the similarities in LOC tag diversity
appear to result from the more rapid LOC tag diversification with
the single cell clones rather than tumorigenesis bottlenecks.
Another way to detect localized selection is to compare the
diversity within glands with the diversity between glands. In the
absence of selection, older more diverse tumors should have older
more diverse glands. If selection occurs within glands, diversity is
reduced as variant cells are eliminated (Fig 2), and intragland
PWDs should be much smaller than intergland PWDs. Consistent
with a lack of selection, intragland PWDs were nearly as large as
intergland PWDs for the clonal and polyclonal xenografts (Fig 3D).
Deeper Sampling Confirms High Passenger Tag Diversity
In the above studies, only eight tags were sampled per specimen.
To confirm the diversity in the small fragments, 24 tags were
sampled (Fig 4A). Additional new tag patterns were detected with
further sampling, although PWDs were relatively stable after
sampling only eight tags. Average diversity was higher in the
polyclonal versus the clonal xenografts, with averages of 10.8 BGN
and 17.2 LOC unique patterns per 24 sampled tags in the
polyclonal xenografts. Substantial tag variation is present in small
2,000 to 10,000 cell tumor fragments, further suggesting that
selection leading to clonal evolution rarely occurs during xenograft
formation with the Lovo cell line in a nude mouse environment.
High Diversity in Single Human Colorectal Cancer Glands
A prior study inferred that small human CRC glands are diverse
populations [12], but sampled only eight tags per gland. To
confirm that human CRC gland diversity may be high and allow
comparisons with the xenografts, 24 tags were sampled from 2,000
to 10,000 cell gland fragments from five CRCs. The glands were
sampled from opposite sides (‘‘left’’ and ‘‘right’’) of the same
tumor, to allow comparisons of cells located within glands and
between glands from opposite tumor sides.
Human CRC gland diversities were high (between 3 to 23
unique patterns per 24 sampled epialleles) indicating that
neighboring cells are not closely related (Fig 4B). For three less
diverse (‘‘younger’’) cancers (Cancers A,B,C), gland PWDs and
numbers of unique tags per 24 sampled tags were similar to values
in the clonal xenografts. For two more diverse (‘‘older’’) cancers
(Cancers D,E), gland PWDs and numbers of unique tags were
similar to the values in the polyclonal xenograft. Consistent with a
single clonal expansion, diversities were similar between left and
right tumor sides, indicating that both tumor sides are likely to
have similar mitotic ages or numbers of divisions since
transformation [12].
Lower Gland Diversity With Higher Mutation Rates
Low cancer gland diversity does not directly reflect selection
because even without selection a new clonal expansion would
initially be homogeneous. To correct for tumor age, as a rough
approximation, the age of a tumor is the time or numbers of
divisions between cells from opposite tumor sides, because these
cells last shared a common ancestor around the time of trans-
formation [12,15]. Therefore, one can compare gland age with
tumor age by comparing intragland PWDs with PWDs between
glands from opposite cancer sides (Fig 5A). In general, older
tumors had older glands, with intragland PWDs correlated with
intergland PWDs.
If selection depends on mutations, a simple prediction is that
selection should occur more often when mutation rates are
elevated. Two of the five CRCs (Cancers B,C) were deficient in
Weak Selection in Colorectal Cancers
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21657Figure 4. Deeper sampling. A. More unique epiallele patterns are observed within polyclonal cultures and the small xenograft fragments when
sampling is increased to 24 tags. PWD values are relatively stable after 8 sampled tags (for reference, the dotted red lines are the polyclonal cell line
values). B. Deeper sampling of glands from five human CRCs. The three cancers on the left are relatively younger cancers with diversity similar to the
clonal xenografts. The two cancers on the right are relatively older cancers with diversity similar to the polyclonal cell line or xenografts. Consistent
with a single clonal expansion, diversity is similar between right and left parts of the same CRC.
doi:10.1371/journal.pone.0021657.g004
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1000-fold higher mutation rates [16]. Gland PWDs in the MMR
deficient CRCs were lower (intragland to intergland PWDs less
than 50%) relative to the MMR proficient CRCs (Fig 5B). The
lower intragland to intergland PWD ratios in MMR deficient
CRCs suggests selection may more efficiently eliminate less fit
variants when mutation rates are higher. The intragland to
intergland PWD ratios for the three MMR proficient CRCs and
the Lovo xenografts were similar (greater than 50%) suggesting
selection occurs less often in these tumors.
Cancer Stem Cells Appear To Be Frequent in Human
CRCs
A quantitative way to describe selection is to estimate the
numbers of long-lived lineages per cancer gland, which are
effectively CSCs [12]. If selection or extinction occurs frequently,
then long-lived CSC lineages will be few. The number of CSCs
per cancer gland can be estimated from its diversity---genomes
within a gland will be more similar with smaller numbers of CSCs
because somatic alterations cannot accumulate in shorter lived
non-CSCs that rapidly become extinct.
A previous analysis of data with eight tags per gland estimated
relatively high CSC frequencies [12]. With 24 tags per gland,
better estimates of CSC frequencies are possible (Table 1). Cancer
gland diversity was too high for a single CSC per gland and too
low for a scenario in which no extinction occurs. Instead, cancer
gland variation was more consistent with limited cancer cell
extinction, which can be modeled as a stem cell hierarchy with
multiple CSCs per gland producing a limited number of non-CSC
progeny. Probabilistic CSC survival instead of deterministic
asymmetric CSC division was more consistent with the data.
Estimated numbers of probabilistic CSCs per 8,000 cell gland
were between 128 and 2,048. The lowest estimated CSC
frequencies per gland (128 and 256 per gland) were with the
two MMR deficient Cancers B and C, a trend previously noted
when comparing between MMR proficient and deficient CRCs
[12]. In summary, cancer cell extinction appears to have occurred
in all the CRCs, but more extensively in MMR deficient CRC
glands.
Clonal Evolution In Human Tumor Populations
The EDTA gland isolation method may bias sampling to
superficial tumor regions, which may be the oldest part of a tumor
that progresses via clonal evolution (Fig 1). Laser capture
microscopy (LCM) can sample multiple superficial, invasive and
metastatic portions of the same CRC (Fig 6A). Only the BGN tag
was used for analysis because its lower apparent error rate
facilitates detection of recent clonal evolution. The degraded DNA
in the fixed specimens and small numbers of genomes sampled by
LCM hinders characterization of intragland PWD, but it is
possible to compare intergland PWDs to search for focal regions of
homogeneity created by recent clonal evolution. Consistent with
the ability to measure tumor diversity with LCM, intergland
PWDs were similar for Cancers A–E whether calculated from
LCM or EDTA gland data (Fig S2).
With sequential stepwise progression, there should be a diversity
gradient (superficial . invasive . metastases), whereas all regions
should be similarly diverse if a tumor is essentially a single clonal
expansion. Nine CRCs were examined (Fig 6B). Diversity was
generally high, and none appeared to be recent clonal expansion
because they all had average intergland PWDs greater than the
clonal xenografts.
Intergland PWDs were similar between superficial and invasive
portions of three Stage II cancers (B,C,E). For two of the six
metastatic cancers (D and F), superficial, invasive, and metastatic
Figure 5. Intragland versus intergland PWDs. A. Intra- and
intergland PWDs generally correlate. The trend line is based on three
human CRCs, with the two MMR deficient cancers with much lower
intragland PWDs. (circles are human CRCs, triangles are the clonal and
polyclonal xenografts). B. Ratios of intra- to intergland PWDs were
greater than 0.5 except for the MMR deficient CRCs, indicating much
greater extinction within glands of the MMR deficient CRCs.
doi:10.1371/journal.pone.0021657.g005





per gland experimental values within 95% simulation intervals
1 CSC per gland* all CSCs* multiple, immortal* multiple, random*
A No 512 1/34 16/34 25/34 (8) 32/34 (512)
B Yes 128 5/28 3/28 14/28 (4) 22/28 (128)
C Yes 256 0/30 3/30 17/30 (4) 26/30 (256)
D No 512 0/32 15/32 19/32 (16) 26/32 (512)
E No 2048 0/34 22/34 21/34 (32) 26/34 (2048)
*Numbers of experimental values (PWDs within glands or unique tags per 24 sampled tags) within 95% simulation intervals for the four scenarios. Simulated CSC
numbers (multiples of 2) best fitting the multiple immortal or random CSC per gland scenarios are in parentheses.
doi:10.1371/journal.pone.0021657.t001
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node metastases of Cancer F. Significant diversity differences were
present between four primary cancers and their metastases. Both
the invasive and metastatic regions of Cancers H and I were
significantly less diverse than their superficial cancer regions. For
Cancer G, only the metastatic lesion was significantly less diverse.
The metastasis of Cancer A was significantly more diverse than its
primary.
To search for regional clonal evolution, intergland PWDs were
compared with physical distances (Fig 6C). The superficial,
invasive and metastatic regions of seven cancers appeared to be
single clonal expansions because there were no significant changes
in PWDs with physical distances. The superficial regions of
Cancers B and D showed a significant increase in PWDs with
physical distances, suggesting adjacent tumor areas were more
related than distant areas. In summary, the diversity of different
parts of the same cancer cannot be predicted, with examples of
metastatic regions with intergland PWDs that were the same,
greater, or smaller than their superficial regions. However,
evidence of recent stepwise progression was lacking because all
Figure 6. Diversity in human invasive and metastatic CRCs. A. Diagram of the LCM sampling of Cancers A and D. Dots are locations of the
superficial (blue), invasive (black), and metastatic (red) regions. (bar is 1 cm wide). B. Comparison of intergland PWDs in the superficial (blue), invasive
(black) and metastatic (red) regions of the nine CRCs. PWDs between individual LCM samples (‘‘X’’) are scattered, with averages represented by the
bars. The scatter of the PWDs between individual glands is expected because of the stochastic nature of replication errors, and regions within the
same tumor that were significantly different (arrows) from their superficial regions were identified from simulations (see Methods). For reference, the
intergland PWDs of the clonal (dotted green line) and polyclonal xenografts (solid green line) are illustrated. C. Comparisons of intergland PWDs with
physical distances indicate that distant and adjacent glands are similarly related in the superficial (blue), invasive (black) and metastatic (red) regions.
A significant increase in PWDs with physical distance (p,0.05) was observed only for the superficial regions of Cancer B and D.
doi:10.1371/journal.pone.0021657.g006
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clonal xenografts) and focal regional homogeneity was usually not
detectable.
Discussion
Tumor cells encounter and colonize many different microen-
vironments during tumorigenesis, and conceptually selection
efficiently maximizes fitness to drive this progression. Clonal
evolution depends on new driver mutations, which should be
readily generated by the genomic ‘‘instability’’ thought to be
present in many cancers [17]. However, recent CRC genome data
demonstrate relatively low mutation frequencies (,1 per 100,000
bases), consistent with normal mutation and division rates [10].
Neutral passenger mutations predominate [6,7], and therefore
bona fide driver mutations may only rarely emerge in the relatively
short intervals between transformation and tumor removal. If
driver changes are rare, clonal evolution would be rare.
Without a measure of selection it is difficult to judge the roles of
the numerous mutations and epigenetic changes found in cancer
genomes. Selection efficiently optimizes fitness whenever and
wherever opportunities arise, but a practical question is how much
cells differ before selection intervenes. Although selection is difficult
to measure, a selective sweep produces a bottleneck and loss of
cellular diversity. Therefore, the diversity of hitchhiking passenger
changes within a population (Fig 2) is a measure of selection [8]. A
sensitive test for selection is the amount of hitchhiking variation
within small cancer glands because fixation is faster in smaller
populations [9]. The high passenger methylation pattern diversity
measured in this study within and between small CRC gland
fragments suggests selection is a weak force that typically lacks the
minimum ability to sweep even nearby cells. This inferred lack of
selective sweeps after transformation is consistent with the inability
to readily identify additional metastatic driver mutations despite
deep sequencing [2,18]. A recent analysis of cancer genome data
using a very different approach inferred that even driver mutations
may confer relatively small selective advantages [19], which would
also be consistent with the high passenger methylation diversity
observed in cancer cell populations.
If selection is weak and a stepwise acquisition of new capabilities
occurs infrequently, the first transformed cell may already produce
well-adapted and versatile progeny with abilities to invade or
metastasize [3]. Phenotypic progression after transformation
would depend on phenotypic plasticity [4,5], with invasion and
metastasis from aberrant differentiation rather than the selection
of new driver mutations. A single expansion is consistent with the
similar diversities between glands regardless of physical distance in
superficial, invasive, and metastatic lesions. The relatively high
diversities of the CRC metastases imply relatively old populations,
consistent with the early dissemination of tumor cells observed in
experimental systems [20]. Significant diversity differences were
sometimes observed between superficial, invasive, and metastatic
regions of the same tumor. Such differences could represent
stepwise selection, but could also arise without clonal evolution
from different arrival times, with deeply invasive and metastatic
regions colonized later in progression. Regional differences in
mitotic rates could also produce differences, including situations
where metastases are more diverse than their primary tumors. The
high passenger methylation diversities in most CRCs and their
metastases indicate relatively old and stable populations, with
many divisions between transformation and surgery.
Without clonal evolution, present day tumor cells would form a
single population with uncomplicated star-shaped ancestries and
frequent long-lived lineages. The relative diversities within glands
versus between glands (intragland to intergland PWD ratios)
indicate how much remodeling or extinction occurs within glands.
Simulations of cancer gland diversity suggested limited cancer cell
extinction and were consistent with stem cell hierarchies with
multiple long-lived CSC lineages per gland rather than extremely
rare CSCs. CRCs are often resistant to chemotherapy [21], and
greater numbers of long-lived lineages would more efficiently
accumulate pre-existing therapy resistant variants.
Tumor evolution is commonly thought to increase fitness, but if
the first transformed cell is already optimally ‘‘fit’’, its progeny may
suffer from progressive declines in fitness, an asexual reproduction
phenomenoncalled Muller’sRatchet [22]. The limited but relatively
ubiquitous extinction inferred in the CRCs may more represent loss
of less fit variant cells (or background selection [8]) rather than
dominance by more fit variants (Fig 2). Interestingly, passenger
methylation pattern diversity and estimated numbers of CSCs were
less in MMR deficient CRCs, where opportunities for selection
would theoretically be greater because mutation rates are about 100
to 1,000-fold higher [16]. Potentially this lower diversity could reflect
lower proliferation rates, although the intergland tag comparisons
should help normalize mitotic ages between the MMR deficient and
proficient CRCs. However, because mutations are more likely to be
deleterious rather than advantageous, the lower passenger methyl-
ation pattern diversity in MMR deficient CRC glands may also
represent negative selection with increased lineage extinction (fewer
long-lived lineages)rather than positive selection and localized clonal
evolution. This decreased fitness with higher mutation rates may
help account for the better clinical outcomes for patients with MMR
deficient CRCs [23]. A ratchet-like decline in fitness with time may
also help explain why tumor growth progressively slows (Gompert-
zian growth [24]) rather than accelerates after transformation. The
greater extinction with elevated mutation rates likely depends on the
microenvironment because the Lovo cell line is MMR deficient [25]
yet background selection was not as evident during xenograft
formation in immunodeficient nude mice. These observations are
consistent with a hypothesis that MMR deficient CRCs may have
better outcomes because of an immune response to new antigens
created by higher mutation rates [26].
Exactly how individual human tumors progress is uncertain
because serial observations are impractical and unethical. Trans-
lation of traditional molecular phylogeny approaches to somatic cell
populations can potentially reconstruct the pasts of individual
human tumors [27], but many unknowns (including cell prolifer-
ation and death rates, and differences in rates and types of
mutations) can confound analysis. Detailed ancestries are not
possible with the current data, and many mechanisms may
contribute to the high passenger methylation variations observed
in cancer glands. Positive or negative background selection is likely
to occur, but the high passenger methylation pattern diversities
within and between cancer glands appear inconsistent with frequent
orwidespreadclonalevolutionsweepsthatarecommonlypresumed
to occur after transformation. Recent comparisons of copy number
variations between single breast cancer cells from the same tumor
also infer tumor populations emerge suddenly rather than gradually
[28]. Recent cancer genome sequencing studies comparing somatic
mutations from different parts of the same tumor infer evolution
over many years, with many differences between metastases and
primary pancreatic adenocarcinomas [29,30]. The current ap-
proach is potentially complementary to sequence comparisons,
being more suitedto reconstruct more recent evolution over months
instead of years due to higher inferred epigenetic replication error
rates. Advances in sequencing technologies combined with defined
topographical sampling of tumor populations should help recon-
struct how individual human cancers evolve.
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Ethics Statement
CRC samples were obtained in the course of routine clinical care
from theNorris ComprehensiveCancerCenter,withapprovalfrom
our institutional review board (University of Southern California
Health Sciences Campus Institutional Review Board, Proposal
#HS-043078). The mouse xenograft studies were approved by our
institutional review board (University of Southern California
Institutional Animal Care and Use Committee, Protocol # 9606).
Lovo studies
Limiting dilution was used for single cell cloning of the Lovo
CRC cell line [13] into 96 well plates, verified by microscopy.
Xenografts were initiated with subcutaneous injection of one
million cells into nude (nu/nu) mice. On sacrifice, the xenografts
were minced and small 2,000 to 10,000 fragments were isolated
after stirring in an EDTA solution, as previously described for
intestinal tissues [12]. DNA was extracted, bisulfite treated, and
then amplified for the BGN and LOC tags. The PCR products
were cloned into bacteria (TA-cloning kit, Invitrogen) and
individual clones were sequenced.
CRC studies
CRC samples were obtained in the course of routine clinical
care from the Norris Comprehensive Cancer Center, with
approval from our institutional review board. The 24 tags per
gland sampling was performed on previously analyzed tumors
(Cancers A–E are respectively Cancers 10, 3, 4, 12, and 5 in Ref
12). LCM was performed as previously described [12] on
formalin-fixed microscope slides. The entire microdissected areas
(about 1,000 to 2,000 cells) were subjected to bisulfite sequencing.
Simulations of human CRC ancestries with different numbers of
deterministic or probabilistic CSCs [12] were used to estimate
CSC frequencies, and determine whether different parts of the
same tumor (superficial, invasive, metastatic) were different
(significance was when average regional PWDs were outside of
95% simulation intervals).
Supporting Information
Figure S1 Methylation tags. A. Sequences of the LOC and
BGN X-chromosomal tags. Primers are underlined and CpG sites
are highlighted in red. B. Sample data, with 8 epialleles sampled
from each specimen. The polyclonal specimens are more diverse
(higher average PWDs) compared to the clonal culture or
xenograft. Filled circles represent methylated CpG sites.
(PDF)
Figure S2 Intergland PWDs were similar with EDTA- (black) or
LCM-sampling (red) for Cancers A–E, indicating the sampling
approaches are equivalent. Only for Cancer B were the values
significantly different (p,0.05, t-test).
(PDF)
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